Ta strona została przetłumaczona automatycznie i dokładność tłumaczenia nie jest gwarantowana. Proszę odnieść się do angielska wersja za tekst źródłowy.

A Phase II Study of Ivonescimab Combined With Iza-bren in Patients With Advanced Non-Small Cell Lung Cancer. (PEGASUS-Lung)

A Multicenter, Single-Arm, Phase II Study Evaluating the Efficacy and Safety of Ivonescimab Combined With Iza-bren Brengitecan in Patients With Advanced Non-Squamous Non-Small Cell Lung Cancer Resistant to Third-Generation EGFR-TKIs

This is a prospective, multicenter, open-label, single-arm phase II clinical study evaluating the efficacy and safety of ivonescimab (a PD-1/VEGF bispecific antibody) combined with Iza-bren (BL-B01D1; izalontamab brengitecan, an EGFR×HER3 bispecific antibody-drug conjugate) in patients aged ≥18 years with histologically or cytologically confirmed unresectable locally advanced (stage IIIB/IIIC) or metastatic (stage IV) non-squamous non-small cell lung cancer (NSCLC) harboring EGFR-sensitizing mutations (exon 19 deletion or L858R) who have imaging-confirmed disease progression during or after prior third-generation EGFR-TKI therapy. A total of 43 subjects will be enrolled at 3 centers. The primary endpoint is progression-free survival (PFS). Other efficacy endpoints include ORR, confirmed ORR, DCR, DoR, OS, 6- and 12-month PFS rates, and 12- and 24-month OS rates. Safety and tolerability will be assessed, and exploratory analyses will evaluate immune markers, HER3 expression, and EGFR resistance molecular subtypes in relation to clinical efficacy. Treatment is given every 3 weeks: ivonescimab 20 mg/kg intravenously on Day 1; Iza-bren 2.5 mg/kg intravenously on Days 1 and 8. Ivonescimab is infused first, followed by Iza-bren after an interval of ≥30 minutes. Treatment continues until disease progression, intolerable toxicity, initiation of new anti-cancer therapy, death, withdrawal of consent, or a maximum of 24 months of treatment.

Przegląd badań

Status

Jeszcze nie rekrutacja

Szczegółowy opis

Study Design Prospective, multicenter, single-arm phase II study Objectives

Primary objective:

To evaluate the efficacy and safety of ivonescimab combined with Iza-bren in patients with EGFR-sensitizing mutation-positive advanced non-squamous NSCLC after progression on third-generation EGFR-TKIs.

Secondary objectives:

  1. To explore the correlation of baseline and on-treatment peripheral blood immune markers (TILs, PD-L1, cytokine profiles, etc.), HER3 expression levels, and EGFR resistance molecular subtypes (T790M, C797S, MET amplification, etc.) with clinical efficacy;
  2. To analyze efficacy differences in the baseline brain metastasis subgroup and among different EGFR mutation subtypes (19del/L858R);
  3. To explore the association of tumor tissue and peripheral blood immune markers (TILs, PD-L1, cytokine profiles, etc.) with PFS and OS outcomes.

Endpoints

  1. Progression-free survival (PFS), objective response rate (ORR), confirmed objective response rate (cORR), and overall survival (OS); to calculate 6-month and 12-month PFS rates and 12-month and 24-month OS rates;
  2. To evaluate the overall safety and tolerability of the combination regimen, and to describe the type, incidence, severity (CTCAE 6.0), duration, management measures, and outcomes of treatment-related adverse events (TRAEs).

Study Population Pathologically confirmed non-squamous NSCLC harboring EGFR-sensitizing mutations, with imaging-confirmed progression after third-generation EGFR-TKI therapy (age ≥18 years, any sex).

Inclusion/Exclusion Criteria

Inclusion criteria (all must be met):

  1. Voluntary written informed consent and ability to comply with study procedures; age ≥18 years, any sex.

  2. Histologically or cytologically confirmed unresectable locally advanced (stage IIIB/IIIC) or metastatic (stage IV) non-squamous NSCLC (AJCC 8th edition).

  3. EGFR-sensitizing mutation (exon 19 deletion or L858R) confirmed by tissue, cytology, or plasma ctDNA; concomitant resistance mutations such as T790M, C797S, and 861Q are allowed.

  4. Prior standard treatment with a third-generation EGFR-TKI (osimertinib, almonertinib, furmonertinib, etc.), with imaging-confirmed disease progression during or after treatment.

  5. ECOG performance status 0 or 1; expected survival ≥3 months.

  6. At least one measurable target lesion per RECIST v1.1 at baseline (longest diameter ≥10 mm; lymph node short diameter ≥15 mm).

  7. Without transfusion or use of colony-stimulating factors, thrombopoietin, or any cell growth factor within 14 days before screening tests, organ function must meet the following criteria:

    • Hematology: ANC ≥1.5×10⁹/L; PLT ≥75×10⁹/L; Hb ≥90 g/L;
    • Liver function: AST/ALT ≤2.5×ULN (≤5×ULN in patients with liver metastases); total bilirubin ≤1.5×ULN;
    • Renal function: creatinine ≤1.5×ULN; urine protein ≤2+ or ≤1000 mg/24 h;
    • Coagulation: INR and APTT ≤1.5×ULN.
  8. Toxicities from prior anti-cancer therapy have recovered to ≤ grade 1 per NCI-CTCAE v6.0 (except alopecia, fatigue, pigmentation, hypothyroidism stable on hormone replacement, grade 2 peripheral neuropathy after chemotherapy, and other exceptions specified in the inclusion criteria).

  9. Women of childbearing potential and male subjects agree to use effective contraception throughout the study and for 6 months after the last dose; serum pregnancy test is negative at screening for women of childbearing potential.

Exclusion criteria (any one excludes):

  1. Pathology containing small cell lung cancer components, or tumors predominantly large cell carcinoma or squamous cell carcinoma, except: curatively treated basal cell carcinoma of the skin, squamous cell carcinoma of the skin, superficial bladder cancer, cervical carcinoma in situ, breast carcinoma in situ, and/or curatively resected carcinoma in situ that the investigator considers eligible.
  2. Known co-existing targetable driver gene alterations (e.g., MET amplification, ROS1 fusion, etc.) without prior corresponding targeted therapy. (Exception: Patients who are unable to receive such targeted therapy due to definitive medical contraindications, e.g., severe allergy or specific organ dysfunction, and have been strictly evaluated by the investigator).
  3. Isolated disease progression only (oligoprogression) that is suitable for and planned to receive local therapy (e.g., radiotherapy or surgery); or patients who have not developed new systemic progression after prior local therapy.
  4. Prior treatment with ivonescimab, Iza-bren, or other EGFR/HER3-ADC drugs.
  5. Active symptomatic interstitial lung disease; prior drug-induced interstitial pneumonia requiring intravenous steroid intervention.
  6. Uncontrolled active infection, sepsis, or concurrent pulmonary disease causing clinically severe respiratory impairment, including but not limited to: a. any underlying pulmonary disease (e.g., pulmonary embolism, severe asthma, severe chronic obstructive pulmonary disease within 3 months before randomization); b. restrictive lung disease; c. prior pneumonectomy; severe cardiovascular disease (heart failure, history of myocardial infarction, etc.); hepatic or renal failure.
  7. Hypertension uncontrolled by medication: systolic blood pressure ≥160 mmHg or diastolic blood pressure ≥100 mmHg; myocardial infarction, stroke, or aortic dissection within the past 6 months; prior grade ≥3 arterial/venous thromboembolic event.
  8. QT interval prolongation (QTc >450 ms in men or QTc >470 ms in women, calculated using the Fridericia formula), complete left bundle branch block, third-degree atrioventricular block, frequent and uncontrollable arrhythmia (except those stable for 2 weeks after antiarrhythmic drug treatment): e.g., atrial fibrillation, atrial flutter, ventricular fibrillation, ventricular flutter (transient atrial fibrillation/flutter excluded).
  9. Prior grade ≥3 bleeding event; imaging suggests tumor invasion of major vessels with high bleeding risk.
  10. Active autoimmune disease requiring systemic immunosuppressive therapy within the past 2 years; thyroid hormone replacement and topical steroids are not excluded.
  11. History of allogeneic organ transplantation or allogeneic hematopoietic stem cell transplantation.
  12. Systemic anti-cancer therapy (chemotherapy, targeted therapy, immunotherapy) within 4 weeks before screening; major surgery or unhealed severe trauma within 4 weeks; palliative radiotherapy field must not include RECIST target lesions.
  13. Severe hypersensitivity to monoclonal antibodies or any component of ADC formulations.
  14. Pregnant or lactating women.
  15. Concurrent participation in other interventional anti-cancer clinical trials.
  16. Investigator considers the patient unsuitable for participation in this study. Randomization and Intervention Plan Ivonescimab: 20 mg/kg, intravenous infusion on Day 1 of each cycle; first infusion time 60±10 minutes; for patients unable to tolerate a 60-minute infusion, the infusion time may be extended up to 120 minutes; if no infusion reaction occurs, subsequent cycles may be shortened to 30-60 minutes.

Iza-bren: 2.5 mg/kg, intravenous drip on Days 1 and 8 of each cycle; first infusion time ≥120 minutes; after tolerance, it may be adjusted to 60-120 minutes.

Follow-up Plan Treatment-period follow-up: once before each treatment cycle to assess safety and compliance; efficacy follow-up with imaging every 6 weeks.

End-of-treatment (EOT) visit: 28±7 days after the last dose; complete physical examination, laboratory tests, imaging assessment (conditional), and AE follow-up.

Survival follow-up: every 90±7 days after EOT, via outpatient visit, telephone, WeChat, etc.; record survival status, subsequent anti-cancer treatment, and living status.

Sample Size Calculation A total of 43 subjects are planned. Based on the one-sample log-rank method: the expected number of events under the alternative hypothesis is 32.26; with 38 subjects enrolled, the asymptotic power can reach 80.78%, meeting the prespecified power requirement; considering a 10% dropout rate, the final sample size is 43.

Typ studiów

Interwencyjne

Zapisy (Szacowany)

43

Faza

  • Faza 2

Kontakty i lokalizacje

Ta sekcja zawiera dane kontaktowe osób prowadzących badanie oraz informacje o tym, gdzie badanie jest przeprowadzane.

Kontakt w sprawie studiów

Kopia zapasowa kontaktu do badania

Kryteria uczestnictwa

Badacze szukają osób, które pasują do określonego opisu, zwanego kryteriami kwalifikacyjnymi. Niektóre przykłady tych kryteriów to ogólny stan zdrowia danej osoby lub wcześniejsze leczenie.

Kryteria kwalifikacji

Wiek uprawniający do nauki

18 lat do 65 lat (Dorosły, Starszy dorosły)

Akceptuje zdrowych ochotników

Nie

Płeć kwalifikująca się do nauki

Wszystko

Opis

Inclusion Criteria:

  1. Voluntary written informed consent, age ≥18 years, any sex.

  2. Histologically or cytologically confirmed unresectable locally advanced (Stage IIIB/IIIC) or metastatic (Stage IV) non-squamous NSCLC (AJCC 8th edition).

  3. Confirmed EGFR-sensitizing mutation (Exon 19 deletion or L858R) in tissue, cytology, or plasma ctDNA. Concomitant resistance mutations (e.g., T790M, C797S, 861Q) are allowed.

  4. Prior standard treatment with a third-generation EGFR-TKI (e.g., osimertinib, almonertinib, furmonertinib), with imaging-confirmed disease progression during or after treatment.

  5. ECOG performance status of 0 or 1; expected survival ≥3 months.

  6. At least one measurable target lesion per RECIST v1.1 at baseline (longest diameter ≥10 mm, or lymph node short diameter ≥15 mm).

  7. Adequate organ function (without transfusion or growth factors within 14 days prior to screening):

    Hematology: ANC ≥1.5×10^9/L; PLT ≥75×10^9/L; Hb ≥90 g/L. Liver: AST/ALT ≤2.5×ULN (≤5×ULN for liver metastases); Total bilirubin ≤1.5×ULN.

    Renal: Creatinine ≤1.5×ULN; Urine protein ≤2+ or ≤1000 mg/24h. Coagulation: INR and APTT ≤1.5×ULN.

  8. Prior treatment-related toxicities have recovered to ≤ Grade 1 per NCI-CTCAE v6.0 (except for alopecia, fatigue, pigmentation, stable hypothyroidism on hormone replacement, or grade 2 peripheral neuropathy from chemotherapy).

  9. Women of childbearing potential and male subjects agree to use effective contraception throughout the study and for 6 months after the last dose; serum pregnancy test must be negative for women of childbearing potential at screening.

Exclusion Criteria:

  1. Pathology containing small cell lung cancer components, or tumors predominantly large cell carcinoma or squamous cell carcinoma, except: curatively treated basal cell carcinoma of the skin, squamous cell carcinoma of the skin, superficial bladder cancer, cervical carcinoma in situ, breast carcinoma in situ, and/or curatively resected carcinoma in situ that the investigator considers eligible.
  2. Known co-existing targetable driver gene alterations (e.g., MET amplification, ROS1 fusion, etc.) without prior corresponding targeted therapy. (Exception: Patients who are unable to receive such targeted therapy due to definitive medical contraindications, e.g., severe allergy or specific organ dysfunction, and have been strictly evaluated by the investigator).
  3. Isolated disease progression only (oligoprogression) that is suitable for and planned to receive local therapy (e.g., radiotherapy or surgery); or patients who have not developed new systemic progression after prior local therapy.
  4. Prior treatment with ivonescimab, Iza-bren, or other EGFR/HER3-ADC drugs.
  5. Active symptomatic interstitial lung disease; prior drug-induced interstitial pneumonia requiring intravenous steroid intervention.
  6. Uncontrolled active infection, sepsis, or concurrent pulmonary disease causing clinically severe respiratory impairment, including but not limited to: a. any underlying pulmonary disease (e.g., pulmonary embolism, severe asthma, severe chronic obstructive pulmonary disease within 3 months before randomization); b. restrictive lung disease; c. prior pneumonectomy; severe cardiovascular disease (heart failure, history of myocardial infarction, etc.); hepatic or renal failure.
  7. Hypertension uncontrolled by medication: systolic blood pressure ≥160 mmHg or diastolic blood pressure ≥100 mmHg; myocardial infarction, stroke, or aortic dissection within the past 6 months; prior grade ≥3 arterial/venous thromboembolic event.
  8. QT interval prolongation (QTc >450 ms in men or QTc >470 ms in women, calculated using the Fridericia formula), complete left bundle branch block, third-degree atrioventricular block, frequent and uncontrollable arrhythmia (except those stable for 2 weeks after antiarrhythmic drug treatment): e.g., atrial fibrillation, atrial flutter, ventricular fibrillation, ventricular flutter (transient atrial fibrillation/flutter excluded).
  9. Prior grade ≥3 bleeding event; imaging suggests tumor invasion of major vessels with high bleeding risk.
  10. Active autoimmune disease requiring systemic immunosuppressive therapy within the past 2 years; thyroid hormone replacement and topical steroids are not excluded.
  11. History of allogeneic organ transplantation or allogeneic hematopoietic stem cell transplantation.
  12. Systemic anti-cancer therapy (chemotherapy, targeted therapy, immunotherapy) within 4 weeks before screening; major surgery or unhealed severe trauma within 4 weeks; palliative radiotherapy field must not include RECIST target lesions.
  13. Severe hypersensitivity to monoclonal antibodies or any component of ADC formulations.
  14. Pregnant or lactating women.
  15. Concurrent participation in other interventional anti-cancer clinical trials.
  16. Investigator considers the patient unsuitable for participation in this study.

Plan studiów

Ta sekcja zawiera szczegółowe informacje na temat planu badania, w tym sposób zaprojektowania badania i jego pomiary.

Jak projektuje się badanie?

Szczegóły projektu

  • Główny cel: Leczenie
  • Przydział: Nie dotyczy
  • Model interwencyjny: Zadanie dla jednej grupy
  • Maskowanie: Brak (otwarta etykieta)

Broń i interwencje

Grupa uczestników / Arm
Interwencja / Leczenie
Eksperymentalny: Ivonescimab combined with Izabren

Patients receive ivonescimab (20 mg/kg IV on Day 1) and Iza-bren (2.5 mg/kg IV on Days 1 and 8) every 3 weeks (21-day cycle). Treatment continues until disease progression, unacceptable toxicity, or up to 24 months.

20 mg/kg, intravenous infusion on Day 1 of each 21-day cycle.

Inne nazwy:
  • AK112

2.5 mg/kg, intravenous drip on Days 1 and 8 of each 21-day cycle.

Co mierzy badanie?

Podstawowe miary wyniku

Miara wyniku
Opis środka
Ramy czasowe
Progression-Free Survival (PFS)
Ramy czasowe: From the first dose of study treatment until disease progression or death from any cause (assessed every 6 weeks; up to 24 months of study treatment and 24 months of survival follow-up).

PFS is defined as the time from the first dose of study treatment to the first documented disease progression (evaluated by investigators according to RECIST v1.1) or death from any cause, whichever occurs first. Participants who are alive and progression-free at the time of analysis will be censored at the last adequate tumor assessment.

From the first dose of study treatment until disease progression or death from any cause (assessed every 6 weeks; up to 24 months of study treatment and 24 months of survival follow-up).

Miary wyników drugorzędnych

Miara wyniku
Opis środka
Ramy czasowe
Objective Response Rate (ORR)
Ramy czasowe: Up to approximately 24 months.

The proportion of participants with a best overall response of complete response (CR) or partial response (PR), as assessed by investigators according to RECIST v1.1.

Up to approximately 24 months.
Confirmed Objective Response Rate (cORR)
Ramy czasowe: Up to approximately 24 months.

The proportion of participants with a confirmed CR or PR (confirmed by repeat imaging at least 4 weeks later), as assessed by investigators according to RECIST v1.1.

Up to approximately 24 months.
Disease Control Rate (DCR)
Ramy czasowe: Up to approximately 24 months.

The proportion of participants with a best overall response of CR, PR, or stable disease (SD), as assessed by investigators according to RECIST v1.1.

Up to approximately 24 months.
Duration of Response (DoR)
Ramy czasowe: From first documented response to disease progression or death (up to approximately 24 months).

The time from the first documentation of CR or PR to the first documentation of disease progression or death from any cause, whichever occurs first.

From first documented response to disease progression or death (up to approximately 24 months).
Overall Survival (OS)
Ramy czasowe: From the first dose of study treatment to death from any cause (up to approximately 42 months).

The time from the first dose of study treatment to death from any cause.

From the first dose of study treatment to death from any cause (up to approximately 42 months).
6-month and 12-month PFS Rates
Ramy czasowe: At 6, 12 months after the first dose.

The probability of participants remaining progression-free at specific time points, estimated using the Kaplan-Meier method.

At 6, 12 months after the first dose.
12-month and 24-month OS Rates
Ramy czasowe: At 12 and 24 months after the first dose.

The probability of participants remaining alive at specific time points, estimated using the Kaplan-Meier method.

At 12 and 24 months after the first dose.
Safety and Tolerability (Incidence of Treatment-Related Adverse Events)
Ramy czasowe: From the first dose of study treatment until 28 days after the last dose (up to approximately 24 months of treatment).

The incidence, severity (graded by NCI-CTCAE v6.0), duration, and management of treatment-related adverse events (TRAEs).

From the first dose of study treatment until 28 days after the last dose (up to approximately 24 months of treatment).

Inne miary wyników

Miara wyniku
Opis środka
Ramy czasowe
Correlation of Biomarkers with Clinical Efficacy
Ramy czasowe: Baseline, during treatment, and up to approximately 42 months.

To explore the correlation between baseline and on-treatment peripheral blood immune markers (TILs, PD-L1, cytokine profiles, etc.), HER3 expression levels, and EGFR resistance molecular subtypes (T790M, C797S, MET amplification, etc.) with clinical efficacy (e.g., ORR, PFS).

Baseline, during treatment, and up to approximately 42 months.
Efficacy Analysis in Specific Subgroups
Ramy czasowe: Up to approximately 42 months.

To analyze the differences in efficacy (such as ORR and PFS) among patients with baseline brain metastases and different EGFR mutation subtypes (exon 19 deletion vs. L858R).

Up to approximately 42 months.
Association of Immune Markers with Survival Outcomes
Ramy czasowe: Up to approximately 42 months.

To explore the association between tumor tissue and peripheral blood immune markers (TILs, PD-L1, cytokine profiles, etc.) and survival outcomes (PFS and OS).

Up to approximately 42 months.

Współpracownicy i badacze

Tutaj znajdziesz osoby i organizacje zaangażowane w to badanie.

Publikacje i pomocne linki

Osoba odpowiedzialna za wprowadzenie informacji o badaniu dobrowolnie udostępnia te publikacje. Mogą one dotyczyć wszystkiego, co jest związane z badaniem.

Publikacje ogólne

Daty zapisu na studia

Daty te śledzą postęp w przesyłaniu rekordów badań i podsumowań wyników do ClinicalTrials.gov. Zapisy badań i zgłoszone wyniki są przeglądane przez National Library of Medicine (NLM), aby upewnić się, że spełniają określone standardy kontroli jakości, zanim zostaną opublikowane na publicznej stronie internetowej.

Główne daty studiów

Rozpoczęcie studiów (Szacowany)

1 grudnia 2026

Zakończenie podstawowe (Szacowany)

1 czerwca 2030

Ukończenie studiów (Szacowany)

1 czerwca 2030

Daty rejestracji na studia

Pierwszy przesłany

10 listopada 2026

Pierwszy przesłany, który spełnia kryteria kontroli jakości

10 listopada 2026

Pierwszy wysłany (Rzeczywisty)

17 listopada 2026

Aktualizacje rekordów badań

Ostatnia wysłana aktualizacja (Rzeczywisty)

17 listopada 2026

Ostatnia przesłana aktualizacja, która spełniała kryteria kontroli jakości

10 listopada 2026

Ostatnia weryfikacja

1 listopada 2026

Więcej informacji

Terminy związane z tym badaniem

Inne numery identyfikacyjne badania

  • IIT-2026-10-22

Plan dla danych uczestnika indywidualnego (IPD)

Planujesz udostępniać dane poszczególnych uczestników (IPD)?

NIE

Informacje o lekach i urządzeniach, dokumenty badawcze

Bada produkt leczniczy regulowany przez amerykańską FDA

Nie

Bada produkt urządzenia regulowany przez amerykańską FDA

Nie

Te informacje zostały pobrane bezpośrednio ze strony internetowej clinicaltrials.gov bez żadnych zmian. Jeśli chcesz zmienić, usunąć lub zaktualizować dane swojego badania, skontaktuj się z register@clinicaltrials.gov. Gdy tylko zmiana zostanie wprowadzona na stronie clinicaltrials.gov, zostanie ona automatycznie zaktualizowana również na naszej stronie internetowej .

Subskrybuj